The Experts below are selected from a list of 999 Experts worldwide ranked by ideXlab platform
Michael P Heffernan - One of the best experts on this subject based on the ideXlab platform.
-
efficacy and safety of open label ixekizumab treatment in japanese patients with moderate to severe plaque Psoriasis Erythrodermic Psoriasis and generalized pustular Psoriasis
Journal of The European Academy of Dermatology and Venereology, 2015Co-Authors: Hidehisa Saeki, Hidemi Nakagawa, Taeko Ishii, Yoji Morisaki, Takehiro Aoki, P Y Berclaz, Michael P HeffernanAbstract:Background Ixekizumab, an anti-IL-17A monoclonal antibody, demonstrated a high level of efficacy in moderate-to-severe plaque Psoriasis (PP) patients. Objective To evaluate the efficacy and safety of open-label ixekizumab in Japanese patients with moderate-to-severe PP, Erythrodermic Psoriasis (EP) and generalized pustular Psoriasis (GPP). Methods Patients received 160-mg subcutaneous ixekizumab injection at Week 0, 80-mg every 2 weeks through Week 12 and 80-mg every 4 weeks through Week 24. Efficacy and safety are reported through 24 weeks; additional safety data are available for some patients. Results A total of 78 patients with PP, 8 with EP and 5 with GPP enrolled. In PP patients, PASI75 and PASI90 response rates were 98.7% (77/78) and 83.3% (65/78) at Week 12 respectively. In EP patients, PASI75 and PASI90 were 100.0% (8/8) and 62.5% (5/8) and in GPP patients were 80.0% (4/5) and 60.0% (3/5). Overall, 84.0% (76/91) had a treatment-emergent AE through ≥24 weeks. There were no serious AEs, deaths, cases of tuberculosis or invasive fungal infections. Limitations No control group and small sample sizes, especially for EP and GPP. Conclusion By Week 12, nearly all patients with PP, EP and GPP achieved PASI75. The safety profile was consistent with reported results and no unexpected safety signals were observed.
-
Efficacy and safety of open‐label ixekizumab treatment in Japanese patients with moderate‐to‐severe plaque Psoriasis, Erythrodermic Psoriasis and generalized pustular Psoriasis
Journal of the European Academy of Dermatology and Venereology : JEADV, 2014Co-Authors: Hidehisa Saeki, Hidemi Nakagawa, Taeko Ishii, Yoji Morisaki, Takehiro Aoki, P Y Berclaz, Michael P HeffernanAbstract:Background Ixekizumab, an anti-IL-17A monoclonal antibody, demonstrated a high level of efficacy in moderate-to-severe plaque Psoriasis (PP) patients. Objective To evaluate the efficacy and safety of open-label ixekizumab in Japanese patients with moderate-to-severe PP, Erythrodermic Psoriasis (EP) and generalized pustular Psoriasis (GPP). Methods Patients received 160-mg subcutaneous ixekizumab injection at Week 0, 80-mg every 2 weeks through Week 12 and 80-mg every 4 weeks through Week 24. Efficacy and safety are reported through 24 weeks; additional safety data are available for some patients. Results A total of 78 patients with PP, 8 with EP and 5 with GPP enrolled. In PP patients, PASI75 and PASI90 response rates were 98.7% (77/78) and 83.3% (65/78) at Week 12 respectively. In EP patients, PASI75 and PASI90 were 100.0% (8/8) and 62.5% (5/8) and in GPP patients were 80.0% (4/5) and 60.0% (3/5). Overall, 84.0% (76/91) had a treatment-emergent AE through ≥24 weeks. There were no serious AEs, deaths, cases of tuberculosis or invasive fungal infections. Limitations No control group and small sample sizes, especially for EP and GPP. Conclusion By Week 12, nearly all patients with PP, EP and GPP achieved PASI75. The safety profile was consistent with reported results and no unexpected safety signals were observed.
Enzo Errichetti - One of the best experts on this subject based on the ideXlab platform.
-
Erythrodermic Psoriasis: Current and Future Role of Biologicals
BioDrugs, 2015Co-Authors: Giuseppe Stinco, Enzo ErrichettiAbstract:Erythrodermic Psoriasis (EP) is a severe form of Psoriasis that may be associated with serious and sometimes fatal complications. The treatment of EP is often a challenge, since several factors, including treatment failure or possible complications, may limit favorable outcomes with traditional drugs. Recent evidence suggests that biological drugs, including both anti-tumor necrosis factor alpha agents and ustekinumab, may be useful in improving the management of EP. Unfortunately, since subjects with EP are usually excluded from pivotal trials involving biological agents, this evidence is currently dispersed in small case series and single case reports. In this paper, we briefly analyze conventional therapies for EP, before going on to critically evaluate the existing clinical evidence for the role of current biological drugs, namely infliximab, etanercept, adalimumab, and ustekinumab. Finally, we discuss the potential benefits that newer/developmental biological agents could bring to the management of EP.
-
Treatment of recalcitrant Erythrodermic Psoriasis with ustekinumab
European journal of dermatology : EJD, 2014Co-Authors: Giuseppe Stinco, Angelo Piccirillo, Enzo Errichetti, Serena Bergamo, Pasquale PatroneAbstract:Erythrodermic Psoriasis (EP) can be challenging to treat since several factors, such as failure or intolerance, limit favourable outcomes with traditional therapies [1]. The conventional treatments recommended for EP are methotrexate, oral retinoids and cyclosporine [2], although systemic steroids are still used, especially in severe and unstable forms, since they usually induce a rapid clinical improvement [2, 3]. Recently, some cases of EP have been successfully treated with biological agents, [...]
Hidehisa Saeki - One of the best experts on this subject based on the ideXlab platform.
-
efficacy and safety of ixekizumab treatment for japanese patients with moderate to severe plaque Psoriasis Erythrodermic Psoriasis and generalized pustular Psoriasis results from a 52 week open label phase 3 study uncover j
Journal of Dermatology, 2017Co-Authors: Hidehisa Saeki, Hidemi Nakagawa, Ko Nakajo, Taeko Ishii, Yoji Morisaki, Takehiro Aoki, Gregory S Cameron, Olawale OsuntokunAbstract:Psoriasis, a chronic, immune-mediated skin disease characterized by red, scaly plaques, affects approximately 0.3% of the population in Japan. The aim of this open-label study was to evaluate the long-term efficacy and safety of ixekizumab, a humanized, anti-interleukin-17A monoclonal antibody, in Japanese patients with plaque Psoriasis (n = 78, including 11 psoriatic arthritis), Erythrodermic Psoriasis (n = 8) and generalized pustular Psoriasis (n = 5). Ixekizumab was administrated s.c. at baseline (week 0, 160 mg), from weeks 2 to 12 (80 mg every 2 weeks), and from weeks 16 to 52 (80 mg every 4 weeks). At week 52, 92.3% of patients with plaque Psoriasis achieved Psoriasis Area and Severity Index (PASI) 75, 80.8% achieved PASI 90, 48.7% achieved PASI 100, and 52.6% had remission of plaques (by static Physician Global Assessment, sPGA [0]). Difficult to treat areas of Psoriasis (nail or scalp) also responded to ixekizumab. All patients with psoriatic arthritis who were assessed (5/5) achieved an American College of Rheumatology 20 response. Most patients with Erythrodermic Psoriasis or generalized pustular Psoriasis responded to ixekizumab and the clinical outcome was maintained over 52 weeks (75% and 60% of patients achieved sPGA [0, 1] at week 52, respectively). Mostly mild or moderate treatment-emergent adverse events were reported by 79 of 91 patients; the most common were nasopharyngitis, eczema, seborrheic dermatitis, urticaria and injection site reactions. In conclusion, 52-week ixekizumab treatment was efficacious and well tolerated in Japanese patients with plaque Psoriasis. Efficacy was also observed in patients with Erythrodermic Psoriasis, generalized pustular Psoriasis and psoriatic arthritis.
-
efficacy and safety of open label ixekizumab treatment in japanese patients with moderate to severe plaque Psoriasis Erythrodermic Psoriasis and generalized pustular Psoriasis
Journal of The European Academy of Dermatology and Venereology, 2015Co-Authors: Hidehisa Saeki, Hidemi Nakagawa, Taeko Ishii, Yoji Morisaki, Takehiro Aoki, P Y Berclaz, Michael P HeffernanAbstract:Background Ixekizumab, an anti-IL-17A monoclonal antibody, demonstrated a high level of efficacy in moderate-to-severe plaque Psoriasis (PP) patients. Objective To evaluate the efficacy and safety of open-label ixekizumab in Japanese patients with moderate-to-severe PP, Erythrodermic Psoriasis (EP) and generalized pustular Psoriasis (GPP). Methods Patients received 160-mg subcutaneous ixekizumab injection at Week 0, 80-mg every 2 weeks through Week 12 and 80-mg every 4 weeks through Week 24. Efficacy and safety are reported through 24 weeks; additional safety data are available for some patients. Results A total of 78 patients with PP, 8 with EP and 5 with GPP enrolled. In PP patients, PASI75 and PASI90 response rates were 98.7% (77/78) and 83.3% (65/78) at Week 12 respectively. In EP patients, PASI75 and PASI90 were 100.0% (8/8) and 62.5% (5/8) and in GPP patients were 80.0% (4/5) and 60.0% (3/5). Overall, 84.0% (76/91) had a treatment-emergent AE through ≥24 weeks. There were no serious AEs, deaths, cases of tuberculosis or invasive fungal infections. Limitations No control group and small sample sizes, especially for EP and GPP. Conclusion By Week 12, nearly all patients with PP, EP and GPP achieved PASI75. The safety profile was consistent with reported results and no unexpected safety signals were observed.
-
Efficacy and safety of open‐label ixekizumab treatment in Japanese patients with moderate‐to‐severe plaque Psoriasis, Erythrodermic Psoriasis and generalized pustular Psoriasis
Journal of the European Academy of Dermatology and Venereology : JEADV, 2014Co-Authors: Hidehisa Saeki, Hidemi Nakagawa, Taeko Ishii, Yoji Morisaki, Takehiro Aoki, P Y Berclaz, Michael P HeffernanAbstract:Background Ixekizumab, an anti-IL-17A monoclonal antibody, demonstrated a high level of efficacy in moderate-to-severe plaque Psoriasis (PP) patients. Objective To evaluate the efficacy and safety of open-label ixekizumab in Japanese patients with moderate-to-severe PP, Erythrodermic Psoriasis (EP) and generalized pustular Psoriasis (GPP). Methods Patients received 160-mg subcutaneous ixekizumab injection at Week 0, 80-mg every 2 weeks through Week 12 and 80-mg every 4 weeks through Week 24. Efficacy and safety are reported through 24 weeks; additional safety data are available for some patients. Results A total of 78 patients with PP, 8 with EP and 5 with GPP enrolled. In PP patients, PASI75 and PASI90 response rates were 98.7% (77/78) and 83.3% (65/78) at Week 12 respectively. In EP patients, PASI75 and PASI90 were 100.0% (8/8) and 62.5% (5/8) and in GPP patients were 80.0% (4/5) and 60.0% (3/5). Overall, 84.0% (76/91) had a treatment-emergent AE through ≥24 weeks. There were no serious AEs, deaths, cases of tuberculosis or invasive fungal infections. Limitations No control group and small sample sizes, especially for EP and GPP. Conclusion By Week 12, nearly all patients with PP, EP and GPP achieved PASI75. The safety profile was consistent with reported results and no unexpected safety signals were observed.
Corredoira Salum Yamile - One of the best experts on this subject based on the ideXlab platform.
-
Erythrodermic Psoriasis in young man: suspect HIV infection
Sociedad Chilena de Infectología, 2017Co-Authors: Arellano Lorca Javier, Yagnam Mathias, Vidal Martin, Corredoira Salum YamileAbstract:HIV infection can be manifested with different skin symptoms, which are sometimes considered infection markers. Erythrodermic Psoriasis is a possible manifestation, which is a widespread form of Psoriasis. We report a clinical case of a young man suspected of HIV infection due to a psoriatic erythroderma confirmed by biopsies, associated with Kaposi sarcoma. Afterwards, HIV infection was confirmed by serological tests. Antiretroviral therapy was started, with positive response at one month of treatment. Erythrodermic Psoriasis can be considered a skin marker of HIV infection when occurs in previously healthy patients or in recalcitrant Psoriasis.La infección por VIH puede presentarse con distintas manifestaciones cutáneas, que en algunas ocasiones son consideradas marcadores de infección. Una posible manifestación es la eritrodermia psoriática, que corresponde a una forma generalizada de Psoriasis. Presentamos un caso clínico de un hombre joven en que se sospechó una infección por VIH por un cuadro de eritrodermia psoriática confirmada por biopsia, asociado a un sarcoma de Kaposi. Posteriormente, la infección por VIH fue confirmada por serología. Se manejó con terapia antirretroviral, con buena respuesta al mes de tratamiento. La eritrodermia psoriática se puede considerar un marcador cutáneo de infección por VIH cuando ocurre en pacientes previamente sanos o con Psoriasis recalcitrante
-
Erythrodermic Psoriasis in young man: Suspect HIV infection Eritrodermia psoriática en un hombre joven: Sospechar infección por vih
'SciELO Agencia Nacional de Investigacion y Desarrollo (ANID)', 2017Co-Authors: Arellano Javier, Yagnam Mathias, Vidal Martin, Corredoira Salum YamileAbstract:© 2018, Sociedad Chilena de Infectologia. All rights reserved. HIV infection can be manifested with different skin symptoms, which are sometimes considered infection markers. Erythrodermic Psoriasis is a possible manifestation, which is a widespread form of Psoriasis. We report a clinical case of a young man suspected of HIV infection due to a psoriatic erythroderma confirmed by biopsies, associated with Kaposi sarcoma. Afterwards, HIV infection was confirmed by serological tests. Antiretroviral therapy was started, with positive response at one month of treatment. Erythrodermic Psoriasis can be considered a skin marker of HIV infection when occurs in previously healthy patients or in recalcitrant Psoriasis
Giuseppe Stinco - One of the best experts on this subject based on the ideXlab platform.
-
Erythrodermic Psoriasis: Current and Future Role of Biologicals
BioDrugs, 2015Co-Authors: Giuseppe Stinco, Enzo ErrichettiAbstract:Erythrodermic Psoriasis (EP) is a severe form of Psoriasis that may be associated with serious and sometimes fatal complications. The treatment of EP is often a challenge, since several factors, including treatment failure or possible complications, may limit favorable outcomes with traditional drugs. Recent evidence suggests that biological drugs, including both anti-tumor necrosis factor alpha agents and ustekinumab, may be useful in improving the management of EP. Unfortunately, since subjects with EP are usually excluded from pivotal trials involving biological agents, this evidence is currently dispersed in small case series and single case reports. In this paper, we briefly analyze conventional therapies for EP, before going on to critically evaluate the existing clinical evidence for the role of current biological drugs, namely infliximab, etanercept, adalimumab, and ustekinumab. Finally, we discuss the potential benefits that newer/developmental biological agents could bring to the management of EP.
-
Treatment of recalcitrant Erythrodermic Psoriasis with ustekinumab
European journal of dermatology : EJD, 2014Co-Authors: Giuseppe Stinco, Angelo Piccirillo, Enzo Errichetti, Serena Bergamo, Pasquale PatroneAbstract:Erythrodermic Psoriasis (EP) can be challenging to treat since several factors, such as failure or intolerance, limit favourable outcomes with traditional therapies [1]. The conventional treatments recommended for EP are methotrexate, oral retinoids and cyclosporine [2], although systemic steroids are still used, especially in severe and unstable forms, since they usually induce a rapid clinical improvement [2, 3]. Recently, some cases of EP have been successfully treated with biological agents, [...]